192944-99-3Relevant academic research and scientific papers
Disubstituted indazoles as potent antagonists of the integrin α(v)β3
Batt, Douglas G.,Harlow, Patricia P.,Barbera, Frank A.,Spitz, Susan M.,Wexler, Ruth R.,Jadhav, Prabhakar K.,Petraitis, Joseph J.,Houghton, Gregory C.,Modi, Dilip P.,Cain, Gary A.,Corjay, Martha H.,Mousa, Shaker A.,Bouchard, Peter J.,Forsythe, Mark S.
, p. 41 - 58 (2000)
A new series of indazole-containing α(v)β3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 29
Integrin receptor antagonists
-
, (2008/06/13)
This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
